Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CART-ddBCMA |
| Trade Name | |
| Synonyms | Anitocabtagene autoleucel |
| Drug Descriptions |
CART-ddBCMA are autologous T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) with a synthetic antigen-binding domain targeting BCMA (TNFRSF17) and containing CD137 (4-1BB) and CD3 zeta signaling domains, which potentially have antitumor activity (PMID: 35468618). |
| DrugClasses | TNFRSF17 Immune Cell Therapy 27 |
| CAS Registry Number | NA |
| NCIT ID | C199003 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ACLX-001 + CART-ddBCMA | ACLX-001 CART-ddBCMA | 0 | 0 |
| CART-ddBCMA | CART-ddBCMA | 0 | 4 |